Why does eating a cannabis-derived product feel different from inhaling it?

The routes produce different pharmacokinetic profiles. Swallowed formulations pass through first-pass hepatic metabolism before reaching circulation, which converts a portion of the original compound into metabolites and slows onset considerably — typically 60 to 120 minutes to peak plasma levels. Inhalation delivers the compound to arterial blood within seconds via the alveolar surface, producing a sharper, faster concentration peak. The metabolite mix and distribution to tissues also differ between the two routes.

What does 'bioavailability' actually mean in this context?

Bioavailability refers to the proportion of an administered dose that reaches systemic circulation in an active form. A compound with 10% oral bioavailability means roughly 90% of the swallowed dose is either not absorbed or is metabolised before it enters the bloodstream. Different routes produce different bioavailability figures for the same compound — inhalation generally achieves higher bioavailability than oral dosing for lipophilic cannabinoids, though individual variation and formulation factors introduce significant variation around any average figure.

Is a topical cannabinoid product the same as a transdermal one?

Not necessarily. 'Topical' generally describes products designed to act locally in the skin and underlying tissue without achieving significant systemic concentrations. 'Transdermal' specifically refers to delivery designed to cross the full skin barrier and reach the bloodstream. The distinction matters pharmacologically, but product labelling in the consumer market doesn't always use these terms precisely. Genuine transdermal delivery typically requires specialised formulation technology — permeation enhancers or patch systems — not just a cream or balm applied to the surface.

Why are peptides usually injected rather than swallowed?

Peptides are chains of amino acids held together by peptide bonds, and those bonds are vulnerable to the acid environment of the stomach and to digestive proteases in the gastrointestinal tract. Most therapeutic peptides would be broken down into fragments before absorption if swallowed, which is why subcutaneous or other injectable routes are standard in clinical medicine. Oral peptide delivery is an active area of pharmaceutical research, but it remains technically difficult and most current approved peptide medicines use injectable routes.

How does Australian regulation treat different routes of administration for cannabinoid medicines?

In Australia, the TGA evaluates approved cannabinoid medicines under the Therapeutic Goods Act 1989 and the Poisons Standard. The specific approved formulation — including its route of administration — is part of the ARTG listing. Scheduling (Schedule 4 or Schedule 8) is tied to the compound and its concentration, not purely the route, but the route is assessed as part of the product's safety and quality profile. Prescription access through the Special Access Scheme or an Authorised Prescriber applies to all approved routes.

Routes of Administration Compared

By Tom Whitfield · 27 June 2026 · 7 min read

a person pouring liquid into a blue bowl

The route is the message

Thirty-seven seconds. That's roughly how long inhalation takes to move a lipophilic compound from the lung surface into systemic circulation. Compare that to a swallowed capsule, which might take ninety minutes to reach peak plasma concentration after fighting its way through gastric acid, intestinal wall enzymes, and the full machinery of first-pass metabolism. Same molecule, wildly different timeline.

Route of administration is one of the most under-discussed variables in plant-based medicine pharmacology. Most explainers spend their time on which compounds exist , on cannabidiol, on tetrahydrocannabinol, on the terpenes that accompany them , but far less time on the physical and biochemical journey each of those compounds takes from formulation to receptor. That journey matters enormously. It shapes onset time, duration, effective concentration at target tissues, and the metabolite profile the body ultimately produces.

I've spent enough time in biomedical database stacks to find this genuinely fascinating. And I'll be honest: the first time I mapped out the oral versus inhaled bioavailability data side by side, I felt the same small thrill I get spotting a new wader at Nudgee Beach. Which tells you quite a lot about my idea of a good Tuesday.

Oral and oral-mucosal: two very different things under one roof

People use "oral" as if it's a single route. It isn't.

Swallowed formulations , capsules, oils, edibles; enter the gastrointestinal tract and are absorbed primarily across the small intestinal wall. From there they travel via the portal vein directly to the liver before reaching systemic circulation. That first-pass hepatic passage is the key variable. Cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9, metabolise a significant fraction of the dose before it ever reaches the bloodstream in its original form. Oral bioavailability for cannabinoids in particular is highly variable: published estimates in peer-reviewed literature sit somewhere between 4% and 20%, depending on the formulation, the lipid content of any co-administered food, and individual metabolic variation.

Sublingual and buccal delivery, oils held under the tongue, dissolving strips placed against the gum, bypass a portion of first-pass metabolism by absorbing directly through the oral mucosa into the sublingual venous plexus. Onset is faster than swallowing, typically 15–45 minutes rather than 60–120, though some of the dose is still inevitably swallowed and follows the gastrointestinal route anyway. The oral mucosa is richly vascularised but also thin and permeable only to sufficiently lipophilic molecules at physiological pH, so formulation chemistry still matters a great deal.

Inhalation: fast but complicated

The alveolar surface area of human lungs is roughly 70 square metres; about the size of half a singles tennis court, and it's in direct contact with capillary blood flow. Lipophilic compounds crossing that membrane reach arterial circulation within seconds, which is why inhaled pharmacokinetics look so different from oral ones. Bioavailability via inhalation can reach 10–35% or higher, partly because first-pass metabolism is largely bypassed, and the speed of absorption means the concentration-time curve is steep and narrow: a sharp peak, then relatively rapid redistribution into adipose tissue.

But inhalation is not a monolith either. Vaporisation of dried plant material operates differently from a liquid aerosol device. Temperature dramatically affects what volatilises: different compounds within the same plant matrix have distinct boiling points, so the temperature chosen during vaporisation alters the ratio of compounds delivered, including terpenes and minor cannabinoids. This is one reason researchers studying full-spectrum preparations note that the route interacts with the complexity of the formulation itself.

Topical and transdermal: keeping things local (mostly)

Topical application targets the skin and the tissues immediately beneath it. The stratum corneum, the outermost layer of the epidermis; is a formidable barrier. Most topically applied cannabinoids penetrate into the dermis and subcutaneous tissue but do not reach measurable systemic concentrations under typical use conditions. This makes topical preparations physiologically quite different from other routes: whatever receptor interactions occur tend to be localised, engaging receptors expressed peripherally in skin, joints, and nearby nervous tissue rather than those in the central nervous system via circulating blood.

Transdermal delivery is a more specific term: it refers to formulations designed to cross the full skin barrier and achieve systemic concentrations, usually through permeation enhancers, patch technology, or nanoparticle carriers. Genuine transdermal delivery of cannabinoids is an active area of pharmaceutical research, but the products that describe themselves as transdermal in the consumer market vary enormously in whether they actually achieve this.

Subcutaneous and other injectable routes

For peptide-based compounds, injection bypasses all the enzymatic degradation that would otherwise destroy a peptide chain in the gastrointestinal tract. A subcutaneous injection deposits the compound into the loose connective tissue beneath the skin, where it is absorbed into capillaries at a rate governed by local blood flow and the formulation's physicochemical properties.

This is the standard route for several classes of peptide, including GLP-1 receptor agonists used in clinical medicine. Oral peptide delivery remains technically difficult, the acidic gastric environment and protease activity in the gut are hostile to most peptide bonds, which is why injectable formats remain the clinical norm. It's worth keeping in mind here that many peptide products marketed for performance or anti-ageing purposes in Australia are unapproved goods; supplying them without TGA approval is illegal under the Therapeutic Goods Act 1989, and the TGA has been actively enforcing compliance in this space.

How route interacts with formulation complexity

This is where it gets genuinely interesting to me, and I'd argue it's the piece most people skip over too quickly.

A full-spectrum extract and an isolate of the same primary compound are not simply interchangeable because they share a primary active ingredient. The accompanying minor cannabinoids; cannabigerol, for instance, or various terpenes, have their own absorption kinetics and their own metabolic fates. When those compounds are absorbed at different rates by different routes, the ratios arriving at target tissues shift. A sublingual full-spectrum oil and an inhaled version of the same botanical matrix will not produce identical profiles at the receptor level, even if the starting dose is nominally the same.

This matters for how researchers interpret study data. Comparing an inhaled preparation in one trial to an oral one in another and drawing direct conclusions about a compound's characteristics is methodologically shaky, and I'd push back against any literature summary that doesn't flag route as a primary variable.

The endocannabinoid system is distributed across the body in ways that mean the route-dependent distribution pattern of cannabinoids also shapes which receptor populations are most exposed. CB1 receptors are concentrated in the central nervous system; CB2 receptors are more prevalent peripherally, in immune tissue and elsewhere. A topical preparation that stays in peripheral tissue will interact differently with this distribution than a swallowed one that achieves CNS penetration.

Regulatory and scheduling context

In Australia, the route of administration is part of what drives scheduling under the Poisons Standard. Oral prescription cannabinoid medicines, for example, fall under Schedule 4, while higher-concentration THC products attract Schedule 8 controlled drug status. Access pathways, the Special Access Scheme or via an Authorised Prescriber; apply regardless of route, but the specific approved formulation and its route are part of what the TGA evaluates for products listed on the ARTG.

Route matters to regulators not just as a delivery detail but as a core safety and quality parameter. Good Manufacturing Practice requirements for injectable preparations are more stringent than for topical ones, for obvious reasons. The manufacturing classification follows the clinical stakes of the route.

A note on the research gaps

Honest assessment of the pharmacokinetic literature: it's thinner than it should be, and most human bioavailability studies have small sample sizes, short follow-up, and populations that don't reflect the diversity of actual users. A lot of what gets cited in popular writing derives from rodent models, which have different metabolic profiles. I keep a running note in our reference library flagging studies that conflate routes in their methodology sections. It's a longer list than I'd like.

The science here is real and the underlying pharmacokinetic principles are well established. But anyone presenting definitive numbers for bioavailability by route as if they're settled constants is overstating what the current evidence base actually supports.

Sources

, Tom Whitfield, Health librarian, references & fact-checking

Common questions

Why does eating a cannabis-derived product feel different from inhaling it?: The routes produce different pharmacokinetic profiles. Swallowed formulations pass through first-pass hepatic metabolism before reaching circulation, which converts a portion of the original compound into metabolites and slows onset considerably — typically 60 to 120 minutes to peak plasma levels. Inhalation delivers the compound to arterial blood within seconds via the alveolar surface, producing a sharper, faster concentration peak. The metabolite mix and distribution to tissues also differ between the two routes.
What does 'bioavailability' actually mean in this context?: Bioavailability refers to the proportion of an administered dose that reaches systemic circulation in an active form. A compound with 10% oral bioavailability means roughly 90% of the swallowed dose is either not absorbed or is metabolised before it enters the bloodstream. Different routes produce different bioavailability figures for the same compound — inhalation generally achieves higher bioavailability than oral dosing for lipophilic cannabinoids, though individual variation and formulation factors introduce significant variation around any average figure.
Is a topical cannabinoid product the same as a transdermal one?: Not necessarily. 'Topical' generally describes products designed to act locally in the skin and underlying tissue without achieving significant systemic concentrations. 'Transdermal' specifically refers to delivery designed to cross the full skin barrier and reach the bloodstream. The distinction matters pharmacologically, but product labelling in the consumer market doesn't always use these terms precisely. Genuine transdermal delivery typically requires specialised formulation technology — permeation enhancers or patch systems — not just a cream or balm applied to the surface.
Why are peptides usually injected rather than swallowed?: Peptides are chains of amino acids held together by peptide bonds, and those bonds are vulnerable to the acid environment of the stomach and to digestive proteases in the gastrointestinal tract. Most therapeutic peptides would be broken down into fragments before absorption if swallowed, which is why subcutaneous or other injectable routes are standard in clinical medicine. Oral peptide delivery is an active area of pharmaceutical research, but it remains technically difficult and most current approved peptide medicines use injectable routes.
How does Australian regulation treat different routes of administration for cannabinoid medicines?: In Australia, the TGA evaluates approved cannabinoid medicines under the Therapeutic Goods Act 1989 and the Poisons Standard. The specific approved formulation — including its route of administration — is part of the ARTG listing. Scheduling (Schedule 4 or Schedule 8) is tied to the compound and its concentration, not purely the route, but the route is assessed as part of the product's safety and quality profile. Prescription access through the Special Access Scheme or an Authorised Prescriber applies to all approved routes.